Valuation: Lantheus Holdings, Inc.

Capitalization 4.6B 3.88B 3.54B 3.38B 6.27B 418B 6.51B 41.14B 16.35B 201B 17.25B 16.9B 706B P/E ratio 2025 *
22x
P/E ratio 2026 * 18.3x
Enterprise value 4.79B 4.04B 3.68B 3.51B 6.52B 435B 6.77B 42.8B 17.01B 209B 17.95B 17.58B 735B EV / Sales 2025 *
3.19x
EV / Sales 2026 * 3.05x
Free-Float
95.68%
Yield 2025 *
-
Yield 2026 * -
1 day+0.35%
1 week+4.76%
Current month+5.16%
1 month+6.82%
3 months+34.04%
6 months+25.73%
Current year+5.74%
1 week 64.52
Extreme 64.52
70.74
1 month 63.37
Extreme 63.37
70.74
Current year 63.37
Extreme 63.37
70.74
1 year 47.25
Extreme 47.25
111.29
3 years 47.25
Extreme 47.25
126.89
5 years 17.27
Extreme 17.27
126.89
10 years 1.82
Extreme 1.82
126.89
Manager TitleAgeSince
Chief Executive Officer 66 31/12/2025
Director of Finance/CFO 60 20/09/2018
Chief Tech/Sci/R&D Officer 64 31/07/2025
Director TitleAgeSince
Director/Board Member 80 30/04/2012
Chairman 66 29/02/2024
Director/Board Member 61 31/12/2016
Change 5d. change 1-year change 3-years change Capi.($)
+0.35%+4.76%-15.63%+17.83% 4.6B
+1.41%+0.26%+118.15%+270.12% 13.51B
+0.33%-1.96%-19.91%-3.42% 12.9B
-0.67%-3.68%-19.92%-15.20% 5.92B
+0.22%-7.58% - - 5.82B
-5.80%-9.34%-32.79%-41.89% 4.59B
-0.25%-1.23%-13.71%-45.69% 2.99B
-1.62%-3.08%-5.54%-18.03% 2.51B
+4.42%-2.30%+55.02%-63.75% 2.31B
-1.08%-1.89%+115.46%+130.61% 1.76B
Average -0.26%-1.40%+20.12%+25.62% 5.69B
Weighted average by Cap. -0.00%-0.72%+24.94%+64.68%

Financials

2025 *2026 *
Net sales 1.5B 1.27B 1.16B 1.1B 2.05B 136B 2.12B 13.43B 5.34B 65.65B 5.63B 5.52B 231B 1.5B 1.27B 1.16B 1.1B 2.05B 136B 2.12B 13.43B 5.34B 65.67B 5.63B 5.52B 231B
Net income 220M 186M 169M 162M 300M 19.99B 311M 1.97B 782M 9.62B 826M 809M 33.79B 250M 211M 192M 183M 340M 22.67B 353M 2.23B 887M 10.91B 936M 917M 38.33B
Net Debt 186M 157M 143M 136M 254M 16.89B 263M 1.66B 661M 8.13B 698M 683M 28.55B -18.51M -15.61M -14.24M -13.58M -25.22M -1.68B -26.17M -165M -65.77M -809M -69.4M -67.98M -2.84B
Logo Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. It classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, and others. Its pipeline includes B amyloid positron emission tomography (PET) imaging agent, NAV-4694, also known as F18-flutafuranol. It has pre-clinical assets, specifically the TROP2 and DUNP19.
Employees
808
Date Price Change Volume
17/02/26 70.49 $ +1.60% 85,337
13/02/26 69.38 $ +0.96% 664,414
12/02/26 68.72 $ +2.14% 1,115,848
11/02/26 67.28 $ +0.16% 965,146
10/02/26 67.17 $ +3.01% 798,268
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
69.38USD
Average target price
84.62USD
Spread / Average Target
+21.96%

Quarterly revenue - Rate of surprise